Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-03-25

FDA Approved: FINTEPLA — Supplemental Application (UCB, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Fintepla (fenfluramine) submitted by UCB, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Fintepla (Fenfluramine)

Snippet

SUPPL AP for FINTEPLA (FENFLURAMINE)